微电生理收盘下跌1.06%，滚动市盈率140.53倍，总市值92.43亿元

Group 1 - The core business of the company is the research, development, production, and sales of innovative medical devices in the field of electrophysiological interventional diagnosis and ablation treatment [2] - The company aims to provide globally competitive integrated solutions for diagnosis and ablation treatment, centered around precise interventional navigation [2] - The company has a range of products including the Columbus 3D cardiac electrophysiology mapping system and various disposable catheters and ablation devices [2] Group 2 - As of the latest financial report for Q1 2025, the company achieved a revenue of 104 million yuan, representing a year-on-year increase of 16.77%, and a net profit of 17.87 million yuan, up 328.63% [3] - The company's gross profit margin stands at 60.56% [3] - The company's current price-to-earnings (PE) ratio is 140.53, significantly higher than the industry average of 51.36 [3]